Monotherapy for postmenopausal women w/ estrogen receptor +ve & HER2 -ve if not previously treated w/ endocrine therapy, locally advanced or metastatic breast cancer w/ disease relapse on or after adjuvant endocrine therapy or disease progression on endocrine therapy. In combination w/ ribociclib for postmenopausal women w/ hormone-receptor (HR) +ve, HER2 -ve advanced or metastatic breast cancer as initial therapy or following disease progression. In combination w/ palbociclib for women who have received prior endocrine therapy w/ HR +ve, HER2 -ve locally advanced or metastatic breast cancer.